AU2012335663B2 - Method of treating a proliferative disease - Google Patents

Method of treating a proliferative disease Download PDF

Info

Publication number
AU2012335663B2
AU2012335663B2 AU2012335663A AU2012335663A AU2012335663B2 AU 2012335663 B2 AU2012335663 B2 AU 2012335663B2 AU 2012335663 A AU2012335663 A AU 2012335663A AU 2012335663 A AU2012335663 A AU 2012335663A AU 2012335663 B2 AU2012335663 B2 AU 2012335663B2
Authority
AU
Australia
Prior art keywords
braf
treatment
braf inhibitor
weeks
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335663A
Other languages
English (en)
Other versions
AU2012335663A1 (en
Inventor
Darrin Stuart
Meghna Das THAKUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2012335663A1 publication Critical patent/AU2012335663A1/en
Application granted granted Critical
Publication of AU2012335663B2 publication Critical patent/AU2012335663B2/en
Assigned to ARRAY BIOPHARMA, INC. reassignment ARRAY BIOPHARMA, INC. Request for Assignment Assignors: NOVARTIS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012335663A 2011-11-11 2012-11-09 Method of treating a proliferative disease Active AU2012335663B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
US61/558,619 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
AU2012335663A1 AU2012335663A1 (en) 2014-05-29
AU2012335663B2 true AU2012335663B2 (en) 2015-12-24

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012335663A Active AU2012335663B2 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Country Status (10)

Country Link
US (1) US11007194B2 (enExample)
EP (1) EP2776037B1 (enExample)
JP (1) JP6150813B2 (enExample)
CN (2) CN103917236A (enExample)
AU (1) AU2012335663B2 (enExample)
BR (1) BR112014011223A8 (enExample)
CA (1) CA2855243C (enExample)
MX (1) MX354725B (enExample)
RU (1) RU2622015C2 (enExample)
WO (1) WO2013070996A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP3574904A1 (en) * 2012-08-07 2019-12-04 Array Biopharma, Inc. Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
CN109890386B (zh) 2016-06-03 2022-05-24 阵列生物制药公司 药物组合
WO2018107146A1 (en) * 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
IL294484A (en) * 2020-01-07 2022-09-01 Revolution Medicines Inc Shp2 inhibitor dosing and methods of treating cancer
PE20231651A1 (es) 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
IL132991A (en) 1997-05-22 2005-11-20 Searle & Co Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20050043409A1 (en) 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
BRPI0414698A (pt) 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
BRPI0506760A (pt) 2004-01-09 2007-05-22 Novartis Ag derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inibidores de igf-ir
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
KR20070113295A (ko) 2005-03-17 2007-11-28 노파르티스 아게 티로신/트레오닌 키나제 억제제, 특히 ｂ-ｒａｆ 키나제억제제로서의ｎ-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4ｂ-트리아자플루오렌-9-일)-페닐]벤즈아미드
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
AU2006284053B2 (en) 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
JP2009532497A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2007308045A1 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EA201000113A1 (ru) 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
AU2008313622A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of N-aryl urea-based drugs
AU2008323287B2 (en) 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8129394B2 (en) 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
US20110293750A1 (en) 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
US8524707B2 (en) 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8546413B2 (en) 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EA023942B1 (ru) 2010-01-27 2016-07-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2688572B1 (en) 2011-03-21 2017-05-03 Valcuria AB A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
CA2844407A1 (en) 2011-06-14 2012-12-20 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
KR102091295B1 (ko) 2011-11-23 2020-03-19 어레이 바이오파마 인크. 제약 제제
CA2890663A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pizzolato, N. et al., Theory in Biosciences, 2011, Vol. 130, No. 3, pages 203-210. *
Tomasetti, C. et al., Mathematical Biosciences and Engineering, 2010, Vol. 7, No. 4, pages 905-918. *

Also Published As

Publication number Publication date
AU2012335663A1 (en) 2014-05-29
US20140275136A1 (en) 2014-09-18
JP2014533272A (ja) 2014-12-11
CA2855243A1 (en) 2013-05-16
CN103917236A (zh) 2014-07-09
US11007194B2 (en) 2021-05-18
CN108542906A (zh) 2018-09-18
RU2014117707A (ru) 2015-12-20
RU2622015C2 (ru) 2017-06-08
JP6150813B2 (ja) 2017-06-21
WO2013070996A1 (en) 2013-05-16
MX354725B (es) 2018-03-16
EP2776037B1 (en) 2019-01-09
EP2776037A1 (en) 2014-09-17
CA2855243C (en) 2020-04-14
HK1198920A1 (en) 2015-06-19
BR112014011223A2 (pt) 2017-05-09
MX2014005726A (es) 2014-05-28
BR112014011223A8 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
AU2012335663B2 (en) Method of treating a proliferative disease
Sun et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
Kim et al. MEK inhibitors under development for treatment of non-small-cell lung cancer
Muñoz-Couselo et al. NRAS-mutant melanoma: current challenges and future prospect
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Martinelli et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells
Luke et al. The biology and clinical development of MEK inhibitors for cancer
Sarkisian et al. MEK inhibitors for the treatment of NRAS mutant melanoma
Strumberg et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Fiskus et al. B-Raf inhibition in the clinic: present and future
von Euw et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
Patyna et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
Guillaumond et al. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways
Corrado et al. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis
Stein et al. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma
Evans et al. Current and future trials of targeted therapies in cutaneous melanoma
Sammons et al. Copper suppression as cancer therapy: The rationale for copper chelating agents in BRAF V600 mutated melanoma
Rajendra et al. Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
Imyanitov et al. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
Suryavanshi et al. MEK inhibitors in oncology: a patent review and update (2016–present)
Ding et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2
Francis et al. The current status of targeted therapy for non‐small cell lung cancer
HK1198920B (en) Method of treating a proliferative disease
Crane et al. The therapeutic promise of anti-cancer drugs against the Ras/Raf/MEK/ERK pathway

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ARRAY BIOPHARMA, INC.

Free format text: FORMER OWNER(S): NOVARTIS AG

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO ARRAY BIOPHARMA INC.